{"id":386397,"date":"2020-11-23T01:03:18","date_gmt":"2020-11-23T06:03:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=386397"},"modified":"2020-11-23T01:03:18","modified_gmt":"2020-11-23T06:03:18","slug":"genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/","title":{"rendered":"Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MILAN, Italy and NEW YORK, Nov.  23, 2020  (GLOBE NEWSWIRE) &#8212; Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem progenitor cell gene therapy for cancer (Temferon\u2122), announced\u00a0that highly experienced biotech executive and investor Stephen Squinto, PhD joint Genenta and will be appointed as Chairman of its Board of Directors.<\/p>\n<p align=\"justify\">The appointment will be effective with the approval of the Genenta Shareholders\u2019 Meeting. Pierluigi Paracchi, currently Chairman and Chief Executive Officer of Genenta, will continue to serve as CEO.<\/p>\n<p align=\"justify\">Dr Squinto is currently Executive Partner of the healthcare investment company OrbiMed Advisors and has more than 25 years\u2019 experience in the biotech industry, including as Chief Executive Officer of the gene therapy company Passage Bio. He was a co-founder of Alexion Pharmaceuticals, where he served as Chief Global Operations Officer and Global Head of Research, and previously held several senior leadership positions at Regeneron Pharmaceuticals.<\/p>\n<p align=\"justify\">Dr Squinto currently serves on the Board of Directors of a several biotech and healthcare companies and has received numerous honors and awards from academic and professional organizations for his scientific work. He received his PhD in Biochemistry and Biophysics from Loyola University of Chicago.<\/p>\n<p align=\"justify\">\n        <strong>Pierluigi Paracch<\/strong><br \/>\n        <strong>i<\/strong>, CEO of Genenta, said: \u201cI am delighted to welcome Steve Squinto to Genenta as our new Chairman. Steve will provide valuable input and guidance to the development on Genenta, based on his outstanding and extensive time in biotech industry. In particular, his time as CEO of the gene therapy company Passage Bio provides a clear parallel to Genenta, as we continue to develop the stem cell gene therapy Temferon\u2122.\u201d<\/p>\n<p align=\"justify\">\n        <strong>Stephen Squinto<\/strong> said: \u201cIt as honor to be invited to be Chairman of Genenta, a truly exciting company which has the potential to revolutionize the way we treat cancer through its novel immuno-gene therapy Temferon\u2122. I am looking forward to working with the outstanding team already in place to progress this treatment, which has potential against a broad range of tumors both as first line and as combination therapy, further through clinical trials and towards market.\u201d<\/p>\n<p align=\"justify\">\n        <u>About Genenta Science <\/u>\n      <\/p>\n<p align=\"justify\">Genenta (www.genenta.com) is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for cancer. Temferon\u2122 is based on ex-vivo gene transfer into autologous hematopoietic stem\/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes\/macrophages (Tie2 Expressing Monocytes &#8211; TEMs). Temferon, which is under investigation in a Phase I\/II clinical trial in newly diagnosed Glioblastoma Multiforme patients, is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenge in immuno oncology. Based in Milan, Italy, and New York, USA, Genenta has raised \u20ac33.6 million (~$40 million ) in three separate rounds of financing.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:37%;width:37%;min-width:37%\">\n            <em><br \/>\n              <u>Investor Relator &#8211; LifeSci Advisors:<\/u><br \/>\n            <\/em><br \/>\n            <br \/>Mary-Ann Chang, CFA <br \/>Managing Director <br \/>+44 7483 28.48.53 <br \/><a href=\"mailto:mchang@lifesciadvisors.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mchang@lifesciadvisors.com<\/a>\u00a0<\/td>\n<td style=\"max-width:20%;width:20%;min-width:20%;vertical-align: top\">\n            <em><br \/>\n              <u>Genenta Media\/Investor Contact:<\/u><br \/>\n            <\/em><br \/>\n            <br \/>Stefania Mazzoleni, PhD <br \/>+39 339 709.59 31 <br \/><a href=\"mailto:stefania.mazzoleni@genenta.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">stefania.mazzoleni@genenta.com<\/a>\u00a0<\/td>\n<td style=\"max-width:43%;width:43%;min-width:43%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>GENENTA SCIENCE Srl<\/strong><br \/>\n            <br \/>OSR &#8211; DiBit 1 &#8211; Via Olgettina, 58 &#8211; 20132 Milan (Italy)<br \/>LaunchLabs &#8211; Alexandria Center, 14th Floor <br \/>430 East 29th Street &#8211; New York, NY 10016 (USA)<\/td>\n<\/tr>\n<\/table>\n<p>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDEwNSMzODM3OTA5IzUwMDA3NDY0OA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/0785cd74-bf67-4e5e-b4fb-8c8d2875c0dc\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MILAN, Italy and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem progenitor cell gene therapy for cancer (Temferon\u2122), announced\u00a0that highly experienced biotech executive and investor Stephen Squinto, PhD joint Genenta and will be appointed as Chairman of its Board of Directors. The appointment will be effective with the approval of the Genenta Shareholders\u2019 Meeting. Pierluigi Paracchi, currently Chairman and Chief Executive Officer of Genenta, will continue to serve as CEO. Dr Squinto is currently Executive Partner of the healthcare investment company OrbiMed Advisors and has more than 25 years\u2019 experience in the biotech industry, including as Chief Executive Officer of the gene therapy company Passage Bio. He &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-386397","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MILAN, Italy and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem progenitor cell gene therapy for cancer (Temferon\u2122), announced\u00a0that highly experienced biotech executive and investor Stephen Squinto, PhD joint Genenta and will be appointed as Chairman of its Board of Directors. The appointment will be effective with the approval of the Genenta Shareholders\u2019 Meeting. Pierluigi Paracchi, currently Chairman and Chief Executive Officer of Genenta, will continue to serve as CEO. Dr Squinto is currently Executive Partner of the healthcare investment company OrbiMed Advisors and has more than 25 years\u2019 experience in the biotech industry, including as Chief Executive Officer of the gene therapy company Passage Bio. He &hellip; Continue reading &quot;Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-23T06:03:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDEwNSMzODM3OTA5IzUwMDA3NDY0OA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman\",\"datePublished\":\"2020-11-23T06:03:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\\\/\"},\"wordCount\":515,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDEwNSMzODM3OTA5IzUwMDA3NDY0OA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\\\/\",\"name\":\"Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDEwNSMzODM3OTA5IzUwMDA3NDY0OA==\",\"datePublished\":\"2020-11-23T06:03:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDEwNSMzODM3OTA5IzUwMDA3NDY0OA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDEwNSMzODM3OTA5IzUwMDA3NDY0OA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/","og_locale":"en_US","og_type":"article","og_title":"Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman - Market Newsdesk","og_description":"MILAN, Italy and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; Genenta Science, a clinical-stage biotechnology company pioneering the development of a hematopoietic stem progenitor cell gene therapy for cancer (Temferon\u2122), announced\u00a0that highly experienced biotech executive and investor Stephen Squinto, PhD joint Genenta and will be appointed as Chairman of its Board of Directors. The appointment will be effective with the approval of the Genenta Shareholders\u2019 Meeting. Pierluigi Paracchi, currently Chairman and Chief Executive Officer of Genenta, will continue to serve as CEO. Dr Squinto is currently Executive Partner of the healthcare investment company OrbiMed Advisors and has more than 25 years\u2019 experience in the biotech industry, including as Chief Executive Officer of the gene therapy company Passage Bio. He &hellip; Continue reading \"Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-23T06:03:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDEwNSMzODM3OTA5IzUwMDA3NDY0OA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman","datePublished":"2020-11-23T06:03:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/"},"wordCount":515,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDEwNSMzODM3OTA5IzUwMDA3NDY0OA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/","name":"Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDEwNSMzODM3OTA5IzUwMDA3NDY0OA==","datePublished":"2020-11-23T06:03:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDEwNSMzODM3OTA5IzUwMDA3NDY0OA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDEwNSMzODM3OTA5IzUwMDA3NDY0OA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/genenta-to-appoint-stephen-squinto-experienced-biotech-executive-and-investor-as-chairman\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=386397"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386397\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=386397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=386397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=386397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}